We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+14.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$340M
AUM Growth
+$94.6M
Cap. Flow
+$76.8M
Cap. Flow %
22.61%
Top 10 Hldgs %
47.34%
Holding
100
New
32
Increased
8
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$16.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$12.2M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$9.98M
4
GKOS icon
Glaukos
GKOS
+$9.58M
5
ARWR icon
Arrowhead Research
ARWR
+$8.66M

Top Sells

Rank Stock Value
1
ALIM
Alimera Sciences
ALIM
+$12M
2
ARGX icon
argenx
ARGX
+$9.89M
3
ASND icon
Ascendis Pharma A/S
ASND
+$6.82M
4
INSM icon
Insmed
INSM
+$4.43M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.51M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
2 Consumer Discretionary 1.17%
3 Consumer Staples 0.08%
4 Industrials 0.03%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTTW
76
CDT Equity Inc Warrant
CDTTW
$1.87M
$1.59K ﹤0.01%
100,000
– –
MITAW
77
DELISTED
Coliseum Acquisition Corp. Warrant
MITAW
$1.42K ﹤0.01%
28,333
– –
SRZNW icon
78
Surrozen Inc Warrant
SRZNW
$8.86K
$1.04K ﹤0.01%
82,233
– –
TCBPW
79
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
$343 ﹤0.01%
18,823
– –
ACHV icon
80
Achieve Life Sciences
ACHV
$683M
– –
-216,310
Closed -$1.02M
ALUR
81
DELISTED
Allurion Technologies
ALUR
– –
-38,794
Closed -$968K
BNBX
82
DELISTED
BNB PLUS CORP
BNBX
– –
-115
Closed -$35.2K
APRE icon
83
Aprea Therapeutics
APRE
$7.83M
– –
-137,197
Closed -$558K
ARGX icon
84
argenx
ARGX
$54.1B
– –
-23,000
Closed -$9.89M
ASND icon
85
Ascendis Pharma A/S
ASND
$16.8B
– –
-50,000
Closed -$6.82M
BIVI icon
86
BioVie
BIVI
$7.54M
– –
-19,823
Closed -$794K
CETX icon
87
Cemtrex
CETX
$4.84M
– –
-1
Closed -$74.8K
CNTX icon
88
Context Therapeutics
CNTX
$44.5M
– –
-360,001
Closed -$722K
EVOK
89
DELISTED
Evoke Pharma
EVOK
– –
-57,703
Closed -$366K
INBS icon
90
Intelligent Bio Solutions
INBS
$4.74M
– –
-8,391
Closed -$161K
LXRX icon
91
Lexicon Pharmaceuticals
LXRX
$1.1B
– –
-121,986
Closed -$205K
PMNT
92
DELISTED
PERFECT MOMENT LTD
PMNT
– –
-62,835
Closed -$135K
QNRX
93
Quoin Pharmaceuticals
QNRX
$9.62M
– –
-2,946
Closed -$59.8K
RARE icon
94
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-70,000
Closed -$2.88M
RAPT
95
CALL
DELISTED
RAPT Therapeutics
RAPT
– –
-25,000
Closed -$610K
SVRA icon
96
CALL
Savara
SVRA
$1.19B
– –
-20,000
Closed -$80.6K
BOLD
97
Boundless Bio
BOLD
$65M
– –
-83,149
Closed -$322K
SPRB
98
Spruce Biosciences
SPRB
$129M
– –
-10,816
Closed -$420K
ALIM
99
DELISTED
Alimera Sciences
ALIM
– –
-2,150,000
Closed -$12M
SLNAW
100
DELISTED
Selina Hospitality PLC Warrant
SLNAW
– –
-101,439
Closed -$1.1K
1 2 3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Altium Capital Management held 100 positions worth $340M, up 39% from $245M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Altium Capital Management deployed $76.8M of net new capital in Q3 2024, opening 32 new positions and adding to 8 existing holdings. Its largest new stake was Edwards Lifesciences: 222,000 shares worth $14.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was Insmed, an estimated $4.43M trimmed.

  • Altium Capital Management's largest Q3 2024 buy was Edwards Lifesciences: 222,000 shares worth $14.6M.
  • Altium Capital Management added most to Sarepta Therapeutics in Q3 2024, an estimated $12.2M increase.
  • Altium Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $4.43M.
  • Altium Capital Management fully exited Alimera Sciences in Q3 2024, selling an estimated $12M.
  • Altium Capital Management's ten largest holdings make up 47% of its $340M portfolio in Q3 2024.
  • Altium Capital Management opened 32 new positions and closed 21 in Q3 2024.
  • Altium Capital Management's portfolio value rose 39% quarter-over-quarter to $340M.

Based on Altium Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.